Literature DB >> 8165605

Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.

E M Faioni1, F Franchi, D Asti, E Sacchi, F Bernardi, P M Mannucci.   

Abstract

Nine thrombophilic patients who had had previous diagnoses of functional protein S deficiency were reinvestigated. The functional protein S assays gave dose-response curves that were not parallel to those of the reference plasma. The same pattern was true for approximately half of the first-degree relatives of the propositi. When protein S was extracted from the plasma of the patients by immunoabsorption, it had a normal ratio of functional activity to immunologic concentration. Restriction fragment length polymorphism analysis, informative in one family, showed no linkage between the protein S gene marker and the abnormal behavior of the protein S functional assay. All the propositi and 23/36 first-degree relatives were resistant to the prolongation of activated partial thromboplastin time induced by activated protein C. Furthermore, there was striking concordance in all patients and relatives between the abnormal pattern of the protein S functional assay and resistance to activated protein C. We conclude that a plasma-based functional protein S assay is sensitive to activated protein C resistance and this may lead to spuriously low results in the assay. In agreement with the results of others, this study indicates that resistance to activated protein C is a frequent hemostatic defect in selected thrombophilic populations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8165605

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Genetics and pulmonary medicine. 4. Pulmonary embolism.

Authors:  M Laffan
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 2.  Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.

Authors:  B Dahlbäck
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

3.  Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.

Authors:  B Zöller; P J Svensson; X He; B Dahlbäck
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

4.  Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. luscaber@tin.it.

Authors:  A Girolami; P Simioni; L Scarano; B Girolami; P Zerbinati
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

Review 5.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

6.  Inherited resistance to activated protein C in a boy with multiple thromboses in early infancy.

Authors:  W Zenz; W Muntean; S Gallistl; B Leschnik; A Beitzke
Journal:  Eur J Pediatr       Date:  1995-04       Impact factor: 3.183

7.  Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits.

Authors:  B Arnljots; B Dahlbäck
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

8.  Role of the PROS1 gene in thrombosis: lessons and controversies.

Authors:  Mary J Heeb
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.